BioNTech inks cancer deal with Chinese biotech; Eikon, CASI buy Cleave Therapeutics’ assets
BioNTech has reached a research and option agreement with Biotheus for two antibody candidates.
Biotheus announced the deal Wednesday. It will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
